PFE - Pfizer Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
43.1816
-0.3484 (-0.80%)
As of 9:40AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close43.5300
Open44.0100
Bid43.5000 x 1000
Ask43.4900 x 1100
Day's Range42.7800 - 43.5000
52 Week Range33.2000 - 45.8100
Volume2,180,785
Avg. Volume21,838,732
Market Cap249.61B
Beta (3Y Monthly)0.73
PE Ratio (TTM)10.91
EPS (TTM)3.9590
Earnings DateJan 28, 2019 - Feb 1, 2019
Forward Dividend & Yield1.36 (3.13%)
Ex-Dividend Date2018-11-08
1y Target Est43.79
Trade prices are not sourced from all markets
  • Why Pfizer’s Share Price Fell on November 20
    Market Realist2 hours ago

    Why Pfizer’s Share Price Fell on November 20

    On November 20, Pfizer (PFE) closed at $43.53, which was 1.47% lower than its previous closing price. On November 19, Pfizer and Merck KGaA issued a press release announcing unfavorable results from the Phase 3 trial, JAVELIN Ovarian 200, evaluating avelumab in ovarian cancer indication.

  • Investopedia4 hours ago

    5 Quality Blue Chips to Thrive in Bull and Bear Markets

    As the market grows increasingly turbulent and  economic outlooks become more cautious, investors are increasingly buying quality stocks, which by definition are stocks whose companies are not overly reliant on a robust economy for their performance. In the current environment, Walmart Inc. ( WMT), McDonald’s Corp. ( MCD), Pfizer Inc. ( PFE), Procter & Gamble Co. ( PG) and Amgen Inc. ( AMGN) have all received the quality stamp of approval by Citigroup, according to CNBC.

  • Financial Times8 hours ago

    [$$] Global markets retreat as tech rout spreads

    The savage sell-off of US technology stocks broadened into a global market retreat on Tuesday, stoked by investor fears around trade tension, slowing economic growth and weak corporate earnings in the US, Asia and Europe. The Nasdaq Composite index ended a turbulent trading day down 1.7 per cent, nearly wiping out the last of its gains for the year. It fell 1.8 per cent.

  • Corcept Initiates Phase III Study for Cushing's Syndrome
    Zacks17 hours ago

    Corcept Initiates Phase III Study for Cushing's Syndrome

    Corcept (CORT) doses first patient in the phase III study of relacorilant for the treatment of Cushing's syndrome.

  • Nasdaq Slides More Than 3% As These Dow Blue Chips Buck The Broad Sell-Off
    Investor's Business Daily2 days ago

    Nasdaq Slides More Than 3% As These Dow Blue Chips Buck The Broad Sell-Off

    The Nasdaq got smacked with its biggest single-session loss in more than three weeks and nearly faced a test of the psychologically important 7000 level.

  • The Wall Street Journal18 hours ago

    [$$] Diversis Capital Buys Controlling Stake of Tempo

    Diversis Capital Buys Controlling Stake of Tempo Diversis Capital acquired a controlling interest in Tempo, an Icelandic provider of time-tracking, resource-management and budgeting software. Information-technology services company Origo hf.

  • Pfizer Stock Has Risen ~20% in 2018
    Market Realist20 hours ago

    Pfizer Stock Has Risen ~20% in 2018

    Pfizer’s (PFE) stock price opened at $36.23 on January 2 and reached $43.51 on November 16, which represents ~20.0% growth year-to-date. Pfizer’s stock price closed at $43.51 on November 16, which represents ~31% growth from its 52-week low of $33.20 on February 9.

  • Pfizer's Bavencio Phase III Study for Ovarian Cancer Fails
    Zacksyesterday

    Pfizer's Bavencio Phase III Study for Ovarian Cancer Fails

    Pfizer's (PFE) late-stage advanced ovarian study on Bavencio (avelumab) fails to meet the primary endpoints.

  • Barrons.comyesterday

    Pfizer and 3 Other Stock Picks From a 5-Star Growth Fund

    White Oak Select Growth has returned 16% over the past decade. Here’s what manager Robert Stimpson likes now.

  • 3 Steady Healthcare Stocks to Hold During a Downturn
    InvestorPlace2 days ago

    3 Steady Healthcare Stocks to Hold During a Downturn

    My weekend scanning revealed one prominent theme: The healthcare sector is one of the strongest on the Street making many of its constituents the best stocks to buy for the week ahead. Volume patterns are supporting an optimistic view with numerous accumulation days forming after last month’s earnings report.

  • Pfizer (PFE) Gains As Market Dips: What You Should Know
    Zacks2 days ago

    Pfizer (PFE) Gains As Market Dips: What You Should Know

    Pfizer (PFE) closed the most recent trading day at $44.20, moving +1.57% from the previous trading session.

  • Investopedia2 days ago

    Stock Market Today: Sea of Red

    The selling began early and intensified throughout the day as investors sold nearly everything in sight. Of course, there were a few stocks and sectors that avoided the damage, like Coca-Cola , Verizon and Pfizer , but they were lonely greenshoots in a sea of red. Tech stocks led the bleeding as they have since August, and the headlines were ugly.

  • TheStreet.com2 days ago

    Pfizer Shares Jump on Monday After Company Signals Higher Price Push

    pushed higher on Monday despite defying White House demands to control prices and a broader market selloff. Caitlin Oakley, a spokeswoman for the U.S. Department of Health and Human Services, lambasted the company's move in a statement to Real Money. "Actions announced Friday on list prices further illustrate the perverse incentives of America's drug pricing system," she wrote.

  • Pfizer will raise drug prices come January
    Yahoo Finance Video22 hours ago

    Pfizer will raise drug prices come January

    Pfizer will raise prices on 41 drugs starting January 15, 2019, despite pressure from Trump. Yahoo Finance’s Alexis Christoforous and Communications Director Campaign for Sustainable Rx Pricing Lauren Blair discuss.